Moore, J.; Iheme, N.; Rebold, N.S.; Kusi, H.; Mere, C.; Nwaogwugwu, U.; Ettienne, E.; Chaijamorn, W.; Rungkitwattanakul, D.
Factors and Disparities Influencing Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists Initiation in the United States: A Scoping Review of Evidence. Pharmacy 2025, 13, 46.
https://doi.org/10.3390/pharmacy13020046
AMA Style
Moore J, Iheme N, Rebold NS, Kusi H, Mere C, Nwaogwugwu U, Ettienne E, Chaijamorn W, Rungkitwattanakul D.
Factors and Disparities Influencing Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists Initiation in the United States: A Scoping Review of Evidence. Pharmacy. 2025; 13(2):46.
https://doi.org/10.3390/pharmacy13020046
Chicago/Turabian Style
Moore, Josiah, Ndidi Iheme, Nicholas S. Rebold, Harriet Kusi, Constance Mere, Uzoamaka Nwaogwugwu, Earl Ettienne, Weerachai Chaijamorn, and Dhakrit Rungkitwattanakul.
2025. "Factors and Disparities Influencing Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists Initiation in the United States: A Scoping Review of Evidence" Pharmacy 13, no. 2: 46.
https://doi.org/10.3390/pharmacy13020046
APA Style
Moore, J., Iheme, N., Rebold, N. S., Kusi, H., Mere, C., Nwaogwugwu, U., Ettienne, E., Chaijamorn, W., & Rungkitwattanakul, D.
(2025). Factors and Disparities Influencing Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists Initiation in the United States: A Scoping Review of Evidence. Pharmacy, 13(2), 46.
https://doi.org/10.3390/pharmacy13020046
